Market
Story
Medicare Part D to Cover Eli Lilly’s Zepbound for Sleep Apnea Treatment Following FDA Approval, Creating Opportunity for $LLY
Jan 9, 2025, 02:31 PM
The Centers for Medicare & Medicaid Services (CMS) has announced that Medicare will now cover Eli Lilly's Zepbound for the treatment of obstructive sleep apnea (OSA). This decision follows the drug's recent approval by the FDA, making Zepbound the first medication specifically designed for moderate-to-severe OSA. The coverage under Medicare Part D plans presents a substantial opportunity for Eli Lilly, as it could lead to increased diagnoses and treatment of sleep apnea among patients. However, reports indicate that the costs associated with this coverage could be significant for some patients.
View original story
Similar markets
Surgical Treatments • 25%
Zepbound • 25%
CPAP Machines • 25%
Other Pharmaceuticals • 25%
0 • 25%
5 or more • 25%
3-4 • 25%
1-2 • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
Other • 25%
Novo Nordisk's Wegovy • 25%
Pfizer's Danuglipron • 25%
AstraZeneca's Roxadustat • 25%
20% to 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
More than 30% • 25%
No • 50%
Yes • 50%
2 • 25%
3 or more • 25%
0 • 25%
1 • 25%
Yes • 50%
No • 50%
BEAM-101 leads • 33%
Reni-cel leads • 33%
Casgevy leads • 33%